LSL Pharma Group Inc LSL
TSXV · Canada · Health Technology
CAD 0.2900-0.01 (-3.33%)
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, today announced that Luc Mainville will be leaving his position as Chief Financial Officer of the Corporation, effective immediately.
LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma "), a Canadian integrated pharmaceutical company, today reported its financial results for the second quarter of its 2026 fiscal year, ended June 30, 2026 ("Q2-26" and "YTD 2026"). All amounts are presented in millions of Canadian dollars.
LSL PHARMA GROUP INC. (TSXV: LSL) (The "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to provide an update regarding the remediation plan initiated by Steri-Med Pharma Inc. ("Steri-Med"), as previously announced in the Corporation's news release dated April 30, 2026.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.